Co-trimoxazole 20 — Competitive Intelligence Brief

Co-trimoxazole 20 (Co-trimoxazole 20) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sulfonamide antibiotic combination. Area: Infectious Disease.

marketed Sulfonamide antibiotic combination Dihydropteroate synthase and dihydrofolate reductase Infectious Disease Small molecule

Target snapshot

Co-trimoxazole 20 (Co-trimoxazole 20) — Khon Kaen University. Co-trimoxazole is a fixed-dose combination of sulfamethoxazole and trimethoprim that inhibits bacterial folate synthesis at two sequential steps, preventing DNA replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Co-trimoxazole 20 TARGET	Co-trimoxazole 20	Khon Kaen University	marketed	Sulfonamide antibiotic combination	Dihydropteroate synthase and dihydrofolate reductase
Co-trimoxazole 12	Co-trimoxazole 12	Khon Kaen University	marketed	Sulfonamide antibiotic combination	Dihydropteroate synthase and dihydrofolate reductase
Trimethoprim and sulfamethoxazole	Trimethoprim and sulfamethoxazole	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Sulfonamide antibiotic combination	Dihydropteroate synthase and dihydrofolate reductase
Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim]	Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim]	Fundacion Clinic per a la Recerca Biomédica	marketed	Sulfonamide antibiotic combination	Dihydropteroate synthase and dihydrofolate reductase
Sulfamethoxazole / Trimethoprim Injectable Product	Sulfamethoxazole / Trimethoprim Injectable Product	Fundacion Clinic per a la Recerca Biomédica	marketed	Sulfonamide + dihydrofolate reductase inhibitor combination	Dihydropteroate synthase and dihydrofolate reductase
Intermittent preventive treatment:sulphadoxine-pyrimethamine	Intermittent preventive treatment:sulphadoxine-pyrimethamine	London School of Hygiene and Tropical Medicine	phase 3	Antifolate antimalarial combination	Dihydropteroate synthase and dihydrofolate reductase
Cotrimoxazole dispersible tablet	Cotrimoxazole dispersible tablet	University of Oxford	phase 3	Sulfonamide antibiotic combination	Dihydropteroate synthase and dihydrofolate reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sulfonamide antibiotic combination class)

1. Khon Kaen University · 2 drugs in this class
2. Department of Medical Services Ministry of Public Health of Thailand · 1 drug in this class
3. Fundacion Clinic per a la Recerca Biomédica · 1 drug in this class
4. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
5. University of Oxford · 1 drug in this class